Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.

NCT04061109 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

DRUG: Recombinant Human Coagulation FVIII

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.